Percutaneous Coronary Intervention Use in the United States Defining Measures of Appropriateness by Marso, Steven P. et al.
t
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 5 , N O . 2 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 1 2 . 0 0 4EXPEDITED PUBLICATIONS: VIEWPOINT
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Appropriate utilization of percutaneous coronary intervention (PCI) and medical therapy is deservedly a na-
tional healthcare policy priority for the United States. Because PCI is both common and costly, appraisal of
appropriateness is warranted. The initial appropriate use criteria (AUC) have been developed for coronary
revascularization procedures and investigators recently reported the appropriateness for the approximately
500,000 PCI procedures performed at centers participating in the National Cardiovascular Data Registry. The
AUC have broad implications for both healthcare providers and our patients and will be used as the basis
for indications, referral patterns, treatment options, physician education, shared decision-making, and reim-
bursement for years to come. While we acknowledge the importance of thoughtfully assessing appropriate-
ness for all medical procedures including PCI, there are a number of concerns with the current AUC and
methods used to report appropriateness that warrant expanded commentary. (J Am Coll Cardiol Intv
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warranted. Thus, when a recent appropriateness use
paper was published in the Journal of the American
Medical Association (JAMA), it received national at-
tention and brought again to the forefront the pos-
sibility of PCI overuse in the United States (3).
Following this publication, there was a flurry of
national stories focusing on the apparent overuse of
PCI (4,5). Often, these national stories link the
JAMA paper findings to selected high-profile cases
See page 236
where individual operators are under legal investi-
gation for the systematic overuse of PCI (6). As
practicing clinical cardiologists, we all must re-
main committed to delivering high-quality and
responsive care to our patients. Clinicians should
also strive to offer treatments that minimize the
burden of managing a chronic medical condition
such as coronary artery disease, whether the
burden stems from procedures, office visits, or
medical therapy.
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230The AUC Criteria
The appropriate use criteria (AUC) (7) have far-reaching
implications for the delivery of cardiovascular care for our
deserving patients and for the healthcare providers com-
mitted to serving their needs. As stated in the coronary
revascularization AUC statement, these AUC will be
used as the basis for indications, referral patterns, treat-
ment options, physician education, and shared decision
making for years to come. It is also stated that payers
should use these criteria for the development of “a
rational payment management strategy,” such that mem-
bers would receive effective, safe, and cost-efficient care.
The AUC authors also acknowledge several limitations
inherent in any attempt to codify
clinical decision making. They
state that “these criteria provide
a framework for discussion and
are intended to assist patients
and clinicians, but are not to
diminish the difficulty or uncer-
tainty of clinical decision mak-
ing.” The authors foreshadow
that “many patients in clinical
practice may not be represented
in these initial AUC,” and that
“ranking of an indication as un-
certain should not be viewed as
excluding the use of revasculariza-
tion for such patients.” Last, that
“it is not anticipated that all phy-
sicians or facilities will have 100%
of their revascularization proce-
dures deemed appropriate.”
The interventional cardiology
community must engage in this
national discussion to better for-
mulate a strategy of minimizing
overuse and eradicating the sys-
tematic underuse of effective ther-
apies in the United States. Our failure to adequately do so has
left a large void in this debate.
The AUC Paper
A number of investigators have systematically evaluated the
geographic variability of cardiac catheterization and PCI in
the United States (8–12). Many reference this 2- to 3-fold
variability in the use of PCI as evidence for both over- and
underuse. In a similar fashion, Chan et al. (3) attempt to
describe the appropriateness of PCI in a broad array of PCI
indications at participating NCDR (National Cardiovascu-
Abbreviations
and Acronyms
A  appropriate
ACC  American College
of Cardiology
AUC  appropriate use
criteria
CCS  Canadian
Cardiovascular Society
CTO  chronic total
occlusion(s)
FFR  fractional flow
reserve
I  inappropriate
JAMA  Journal of the
American Medical
Association
LAD  left anterior
descending artery
LV  left ventricular
PCI  percutaneous
coronary intervention
RCA  right coronary artery
U  uncertainlar Disease Registry) CathPCI centers. Although this is a cnoble effort, there are a number of concerns that warrant
expanded commentary.
Misinterpretation of the data. The objective of the Chan et al.
3) paper was to “assess the appropriateness of PCI in the
nited States.” Unfortunately, the overall appropriateness
ate was not presented in the original publication. Rather
he investigators presented the inappropriate rate for acute
nd nonacute indications separately. For acute PCI, the
ajority of indications (98.6%) were mapped as appropriate,
hereas for nonacute PCI, appropriate indications were
ound in only one-half (50.4%) of the sample. In light of the
tated objective of this paper, we believe the editors of the JAMA
nd the investigators should have presented the data in a more
bjective, less “sensational” manner. For the entire population, the
ppropriate (A), uncertain (U), and inappropriate (I) rates for the
00,000 PCI procedures in the JAMA paper were 84.6%, 11.2%,
nd 4.1%, respectively. To present stratified data without provid-
ng the overall inappropriate rate is misleading. As an illustration,
ne could not imagine the original BARI (Bypass Angioplasty
evascularization Investigation) trial manuscript presenting only
he treated diabetic subgroup without including a detailed analysis
rom the overall trial findings (13). Chan et al. (3) also point to a
ide variation in inappropriate PCI as evidence of a culture of
oor patient selection in some centers. They report hospitals in
he lowest quartile had inappropriate rates of 6% or lower
ersus 16% or higher for the highest quartile hospitals. How-
ver, this refers only to nonacute PCIs (28.9% of the entire
tudy group). If we extrapolate this rate of variation to the
ntire study group, the statement would read: Hospitals in the
owest quartile had inappropriate PCI rates of 1.73% or lower
ersus 4.62% or higher for the highest quartile hospitals.
Nevertheless, inappropriate use was identified, which
egs the questions: Is it reasonable to expect a “zero
olerance” for inappropriate PCI rates on a national basis?
nd if there is a tolerable rate of inappropriate PCI, what is
n “acceptable threshold”? Given the current imprecise
ethods used to develop the AUC, a zero frequency is
either expected nor realistic. There remains too much
ncertainty around the mapping of complex clinical scenar-
os when assigning A, U, or I. This fact is acknowledged by
he AUC Writing Committee in the original manuscript.
ecognizing and putting into context the upper threshold is
ifficult. For example, the 1.1% inappropriate rate for the
cute PCI indications might be lower than expected. One
ight reasonably infer from this rate evidence for systematic
nderutilization for the acute indications, as has been
uggested by other data (9). A stated goal of the AUC
ommittee includes using A, U, or I in quality reporting. It
as been suggested that “national norms” will serve as the
hreshold. If that is the case, the AUC committee and
CDR need to understand in detail, the many factors thatontribute to hospital variability.
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231Limitations of the AUC
Lack of concordance between AUC technical panel and
clinical cardiology community. The AUC committee pur-
posefully limited involvement of the interventional commu-
nity during the development process. The AUC guidelines
were devised by a “technical panel created so as to not
include a majority of individuals whose livelihood is tied to
the technology under study.” To prevent bias, “the panel was
deliberately comprised of physicians with varying perspec-
tives on coronary revascularization and not comprised solely
of experts in the procedure undergoing evaluation.” Of the
17 members, only 4 were content experts for PCI indica-
tions. The panel included 4 interventional cardiologists, 4
cardiovascular surgeons, 8 members representing cardiolo-
gists and other medical doctors who treat patients with
cardiovascular disease or health outcome researchers, and 1
health plan medical officer. The motivation for excluding
interventional cardiologists was to prevent financial and/or
intellectual bias from unduly influencing the process. As-
sessing bias at the individual level, whether financial or
intellectual, is challenging. However, assigning bias for
every individual within a medical subspecialty seems overly
judgmental. Clearly, there are U.S. interventional cardiolo-
gists who practice in an environment where remuneration is
not in any way linked to PCI volume. (S.P.M. and J.A.G.
currently practice in such an environment.) There are also
countless excellent international interventional cardiologists
who are both content experts and in no way have a financial
interest in U.S. PCI AUC. Additionally, many argue the
presence of intellectual bias to dismiss individuals (not
entire subspecialities) from participation in committee
meetings. Although there are no statutory or regulatory
criteria to define intellectual bias, and it can be difficult to
identify and/or quantify (14,15), the U.S. Food and Drug
Administration has a vested interest in attempting to
minimize the possibility of intellectual bias among panel
members. Thus, their approach to minimizing intellectual
bias is germane. The current thinking about intellectual bias
at the agency has been revisited recently because of 2
high-profile cases (14). Intellectual bias is believed to exist
when a group member is identified as a strong advocate for
an ideal and a reasonable person would doubt whether he or
she could impartially or objectively offer an opinion. The
Food and Drug Administration evaluates intellectual bias
within individuals. It does not assign intellectual bias to an
entire medical subspecialty.
Limiting the technical panel likely affected the outcome.
There was strong disagreement when the AUC technical
panel rankings were compared with clinical cardiologists’
rankings. Eighty-five cardiologists from 10 U.S. institutions
assessed the appropriateness of coronary revascularization
for 68 indications that had been created by the AUC
Technical Panel (16). This study found excellent concor- Adance (94%) between the AUC Technical Panel and the
larger physician group for appropriate indications. There
was only modest concordance (70%) for inappropriate
indications. Additionally, there was wide variation (i.e.,
nonagreement) in ratings of appropriateness among the
physician group, with more than 25% of physicians assign-
ing an appropriateness category different from the group as
a whole in 2 of every 3 scenarios. This variability was
substantial when correlating individual physicians and the
AUC Technical Panel for inappropriate or uncertain indi-
cations. Moreover, there was substantial variation in appro-
priateness category assignments between individual physi-
cians and the AUC Technical Panel, with some physicians
almost never agreeing with the AUC Technical Panel and
“no physician achieving more than 80% agreement.”
The lack of concordance for the appropriate use scenario
12B was notable and this scenario was the most common
reason for a PCI to be categorized as inappropriate, ac-
counting for 39.6% of all such cases among nonacute
patients. Scenario 12B is described as patients with 1- to
2-vessel disease, no proximal left anterior descending artery
(LAD) involvement or prior coronary artery bypass graft,
class I or II symptoms, low-risk noninvasive findings, and
on no or minimal medications. The median score was
uncertain for the physician group, whereas it was catego-
rized as inappropriate by the technical panel. Chan et al. (3)
argue that the AUC panel serve as the “gold standard” and
that there exists a re-education opportunity for dissenting
physicians. An equally plausible argument is that the AUC
Technical Panel, including the 4 interventional cardiolo-
gists, got this one wrong.
Lack of speciﬁc criteria for interpreting pre-procedural stress
testing. The vast majority of AUC scenarios require knowl-
dge of pre-procedural stress test findings. However, there
re a number of problems regarding the validity and
eliability of assigning a low, intermediate, or high risk to
re-procedural stress testing. The NCDR does not require
nterpreting physicians to determine this risk. Therefore,
his data collection burden falls onto the data abstractors,
ho are required to assign a risk category based on vague
uidelines. Essentially, they are required to interpret the
nterpretation. Various modalities including exercise elec-
rocardiogram, stress echocardiograms, stress single-photon
mission computed tomography, and contrast enhanced
agnetic resonance imaging are accepted by the NCDR
positron emission tomography was not included in the
re-procedural stress testing options). Abstractors are re-
uired to code the test as negative, positive, or indetermi-
ate; if it is positive, abstractors are to assign risk (low,
ntermediate, high, or indeterminate). Unfortunately, the
UC criteria to determine risk, including high risk, are
urprisingly nonspecific. The current recommendations for
ategorizing a stress test as high risk are shown in Table 1.
mong others, a “large stressed induced perfusion defect
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232particularly if anterior” for single-photon emission com-
puted tomography classifies a study as high risk. Neither the
American College of Cardiology (ACC)/NCDR CathPCI
data definitions nor the AUC further define “large perfusion
defect” (17). Likewise, no reference to a definition for
moderate or small defect is provided. There is also no
guidance as to the preferred method for how to quantify the
perfusion defect (sum difference score or polar map meth-
odology) and no statement about how to use the intensity of
ischemia in the determination of risk. This same lack of
specificity exists for other modalities including stress echo-
cardiography. There is also a clerical error in the NCDR
handbook for coders describing a high-risk contrast mag-
netic resonance imaging as a “a large, fixed perfusion defect
with LV dilation or increased lung uptake (thallium-201)
and/or a stress-induced moderate perfusion defect with LV
dilation or increased lung uptake (thallium-201).”
Although it is clear that stress electrocardiogram criteria
can also inform risk (using the Duke treadmill score), the
instructions for the data abstractors do not explicitly guide
them as to when the high-risk electrocardiogram compo-
nent of a stress test should supplant a normal or mildly
abnormal imaging portion. Furthermore, it is not clear how
the abstractors should deal with a presumably false negative
pre-procedural stress test when the coronary angiogram
clearly demonstrates high-risk anatomy and/or fractional
flow reserve (FFR) demonstrates a functionally significant
stenosis confirming the false negative stress test interpreta-
tion. This lack of clarity and specificity in assigning high
risk will lead to considerable hospital variation when docu-
menting stress test risk in the NCDR data case report
forms. It would be interesting to know the degree to which
physicians participated in the ultimate risk assessment that
was entered into the NCDR case report form as opposed to
abstractors getting feedback from the NCDR help line.
Because the appropriateness categories are inexorably linked
to the presence or absence of intermediate/high-risk stress
findings, much of the center level variability in appropriate-
ness may be related to interpretation of stress test findings.
Table 1. High-Risk Nuclear Stress Test Findings According to
the AUC Writing Committee
Resting LVEF 35%
High-risk treadmill score (11)
Severe exercise LVEF 35%
Stress-induced large perfusion defect
Stress-induced multiple perfusion defects
Large, ﬁxed perfusion defect with LV dilation or
increased lung uptake
LV dilation or increased lung uptake
Stress-induced moderate perfusion defect with LV dilation or
increased lung uptake
AUC appropriate use criteria; LV left ventricular; LVEF left ventricular ejection fraction.Future AUC criteria should specifically quantify the area ofischemia and infarction associated with low-, intermediate-,
and high-risk scans. They should comment on intensity of
ischemia. Moreover, the ACC should encourage centers to
clearly summarize this information in stress testing final
reports. The ACC should then increase the emphasis on
center-level education about documenting stress test risk
and then perform repeatability validation studies on a subset
of these results. Last, centers should develop center-level
standard operating procedures to clearly report and collect
key stress test findings such that appropriateness can be
reliably categorized based on stress test findings.
Inability to link stress test results to coronary anatomy.
There is no mechanism for linking the noninvasive test
abnormality to the angiogram. Consider the case of a
patient with class II angina on 1 antianginal drug with
moderate risk right coronary artery (RCA) distribution
ischemia found to have a chronic total occlusion (CTO) of
the RCA and a 70% hemodynamically insignificant lesion in
the proximal LAD. PCI of the proximal LAD lesion would
be categorized as appropriate, whereas a PCI of the RCA
CTO would be inappropriate. Future AUC ought to
develop a strategy to correctly identify whether the culprit
lesion was treated during the percutaneous revascularization
procedure. This could be done by coupling stress test
findings with the target vessel intervention.
Inability to assess appropriateness in stable patients without
pre-procedural stress testing. Though it is often appropriate
to perform stress testing in symptomatic patients to either
estimate the likelihood of coronary artery disease, localize
ischemia, and/or to risk stratify patients before coronary
angiography, it is not medically necessary to do so. Accord-
ing to the Baye theorem, stress testing (for the sole purpose
of identifying coronary artery disease) is not useful in
patients at very high or very low pre-test probability for
coronary artery disease. In fact, doing so is not only
unreliable but adds expense. Even though the AUC com-
mittee acknowledges this, there is an overdependence on
performing pre-procedural stress testing for nonacute PCI
indications. For example, an individual on 1 antianginal
medication with Canadian Cardiovascular Society (CCS)
class III angina found to have a 90% lesion in the proximal
left circumflex was not mapped to A, U, or I in the absence
of stress testing or FFR. This mapping algorithm requires
improvement. There should also be a greater emphasis on
performing FFR of angiographic indeterminate lesions. The
FAME (Fractional flow reserve versus Angiography for
Multivessel Evaluation) trial has informed the medical
community that the probability of an adverse cardiovascular
event is extremely low if FFR is negative (0.80) (18). We
believe this predictive ability is at least as good as (and likely
superior to) the predictive capabilities of noninvasive test-
ing. We firmly believe that pre-procedural stress testing is
not requisite before coronary angiography in all symptom-
atic patients.
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233Angiographic determinants of appropriateness (proximal
LAD and CTO lesions). Very few angiographic variables were
used to assess appropriateness and included only involve-
ment of the left main, proximal LAD and multivessel
disease. The AUC identifies the proximal LAD as a special
region of interest. If PCI was performed in the proximal
LAD, there were no occasions where PCI was inappropriate
for the nonacute indications, as long as patients had not
undergone prior bypass surgery. In these cases, no attempt
was made to assess whether a graft was patent or occluded.
Of the 17,000 inappropriate nonacute PCI cases, 6% were
procedures involving PCI to the proximal LAD among
patients with prior bypass surgery. Future AUC should align
the proximal LAD mapping for patients with and without
prior bypass surgery by collecting graft status.
Both the AUC Technical Panel and the larger physician
group found scenario 14A inappropriate, yet scenarios 30A and
36A uncertain. These three scenarios are nearly identical (1- to
2-vessel disease, no prior coronary artery bypass graft, class I or
II symptoms, intermediate risk from noninvasive findings,
patient on no or minimal medications). Scenario 14 involves
the proximal LAD, whereas scenarios 30 and 36 do not.
Although a superficial understanding of coronary revascular-
ization trials and coronary anatomy seems to justify this
distinction, in practice, coronary anatomy is more complex. In
most cases, the proximal LAD supplies 50% or more of the
myocardium, but there are numerous situations in which
vessels other than the proximal LAD take on equal or more
importance as evidenced by the importance of ischemic burden
on outcomes (19–21). For example, a patient with high-grade
proximal stenosis in a large, dominant circumflex artery, or a
patient with an occluded LAD but disease in a large RCA
and/or circumflex would be extremely dependent on a non-
LAD PCI target.
The only complex lesion subset addressed in the current
AUC is CTO. The rationale for this is unclear. There are a
number of complex lesions that require specific technical
approaches to successfully complete the procedure. Specific
examples include vessels with excessive tortuosity, bifurca-
tion lesions, calcification, ostial lesions, and diffuse disease.
We think incorporating these lesion subsets including
CTO-PCI is beyond the scope of AUC and creates incon-
sistencies. CTOs are commonly found at the time of
coronary angiography and account for 5% to 10% of total
PCIs performed in the United States (22). The expected
benefits of CTO-PCI include symptom relief (23), im-
proved LV function (24), avoidance of other procedures and
possibly improved survival (25,26). Only single-vessel
CTOs are specifically addressed in the AUC. In comparing
single-vessel CTO AUC to 1- or 2-vessel disease not
involving the proximal LAD, there are 5 “downgrades” for
appropriateness of CTO. However, in the presence of
multivessel disease, specific AUC “was not included as a
separate indication since other variations of multivesseldisease are present.” This leads to a paradox when attempt-
ing to incorporate CTO-PCI AUC into clinical practice. In
the setting of multivessel disease, there are no “down
classifications” in appropriateness for CTO revasculariza-
tion. However, if the CTO-PCI is staged after the non-
CTO lesion, its appropriateness designation changes.
CCS class II angina. The AUC generally assigns an inappro-
riate status to CCS class II patients without an attempt at
mproving symptoms with antianginal medications. This
ssignment implies that either PCI is ineffective relative to
edical therapy or that the AUC investigators believe that
edical therapy is preferable to PCI by requiring “pre-
uthorization” before undergoing PCI. The explicit goals of
herapy for managing chronic angina are to prevent major
ardiovascular complications and to relieve symptoms
27,28). Both the COURAGE (Clinical Outcomes Utiliz-
ng Revascularization and Aggressive Drug Evaluation) (29)
nd BARI 2D (Bypass Angioplasty Revascularization In-
estigation 2 Diabetes) trials (27,30) demonstrate that PCI
mproves anginal symptoms in patients with chronic stable
ngina. In the latter trial, Dagenais et al. (30) demonstrate
hat initial coronary revascularization was superior to med-
cal therapy in maintaining freedom from angina, prevent-
ng new onset angina, and arresting worsening angina in
ype 2 diabetic patients during 3 years of follow-up. Differ-
nces between the revascularization and medical therapy
roups were striking during the first year following random-
zation but diminished over time as the medical therapy
mproved their CCS classification. Frequently, individuals
rgue that PCI is costly relative to chronic medical therapy
or the relief of anginal symptoms. However, in a BARI 2D
eport, the lifetime costs of medical therapy were slightly
igher (31). If shared medical decision making is a valued
nformed consent process, physicians ought to have the
pportunity to discuss both PCI and medical therapy with
CS class II patients as being both effective and viable
reatment options. We propose that CCS class II patients
ave significant angina, which is effectively managed with
CI. Future AUC should separate CCS class II from class I
nd acknowledge this in future revisions.
Validation of NCDR data collection. Many AUC-specific data
elements were just recently incorporated into the NCDR
version 4.0 data forms. These data are entirely self-reported
and this effort is unfunded. In contradistinction to current
standards for clinical research, there is minimal monitoring.
Most institutions employ approximately 1 full-time employee
per 1,000 PCIs to address this process, which is less than
one-tenth of the full-time employee ratio employed for most
clinical studies. Furthermore, the data entry fields are usually
completed by catheterization laboratory technologists, nurses,
or cardiology fellows. These individuals have varying expertise,
skills, and interest. Finally, the data can be subject to
“gaming,” wherein symptoms are subtly over- or underre-
ported, lesion stenoses overestimated and medications
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234added only to “upgrade” patient status. The authors of the
JAMA paper argue that by performing their analysis before
making the effort known to interventional cardiologists,
they have likely prevented any gaming of the data. However,
the unintended consequence of this strategy was that many
NCDR centers were not fully prepared to reliably collect
CCS and stress test findings, which undoubtedly led to
substantial misclassification.
Evidence for misclassification surfaced during the validation
of the computer algorithm designed to automap PCI scenarios
to A, U, or I. The JAMA investigators and NCDR requested
that 11 institutions manually map 127 inappropriate proce-
dures. Although they found 100% concordance with the
automated mapping algorithm, there was evidence that the
original source data collected by the institutions was inaccurate.
During the process, it was discovered that 9 cases did not
accurately represent an individual’s angina status and/or non-
invasive risk assessment (S.P.M., J.A.G. personal communica-
tion with Paul S. Chan, October 2011). We believe this should
have prompted further evaluation of these newly launched
AUC-specific data elements. The investigators chose to ignore
this signal and press on with the project and publication plans.
Misclassification also occurred at the primary institution for the
first and senior authors of this viewpoint (S.P.M., J.A.G.),
which is the same institution as the first and senior authors of
the AUC JAMA publication (P.S.C., J.A.S.). We found 56%
of all I cases were misclassified due to incorrectly coding CCS
class status, not documenting angina equivalents, or inaccurate
documentation of the noninvasive risk assessment findings.
We believe the ACC/NCDR should recommit to educating
Table 2. Recommendations for PCI AUC Revisions
Minimizing overuse and underuse of PCI should be a national healthcare priority.
The AUC do not assess effectiveness (PCI can be appropriate without improvement
Scenario 12B (1- or 2-vessel disease, without proximal LAD, low-risk ﬁndings on non
should be changed to uncertain.
The CTO-speciﬁc AUC categories should be removed.
Future AUC should:
Increase the number of clinical scenarios to decrease the unmappable rate (37%
Re-evaluate the need to require a stress test in patients with symptomatic corona
Adopt an intelligent, data-driven strategy to incorporate FFR for culprit lesion ide
The ACC should:
Recommit to educating sites regarding AUC-speciﬁc criteria.
Include bypass graft status
Develop alternative anatomic scenarios that approximate the amount of myocard
Separate CCS class I and II and refrain from requiring pre-procedural stress testing
A greater number of interventional cardiologists need to engage in the AUC proces
Center-speciﬁc recommendations:
Develop an institutional peer review process to evaluate PCI categorized as inapp
Draft standard operating procedures to capture stress test results including abnor
Develop standard operating procedures to speciﬁcally record patients’ reporting o
ACC American College of Cardiology; AUC appropriate use criteria; CCS Canadian Cardiovas
artery; PCI percutaneous coronary intervention.participating NCDR sites on the appropriate collection ofAUC-specific data elements. Until then, it could be argued
that the CathPCI Research and Publications Committee
should refrain from approving AUC-related clinical studies
until such time that assurances are given that these data are
both valid and reliably collected.
In summary, we applaud the work done to date assessing
PCI appropriateness in the United States, but we recognize
that much work remains. Table 2 provides a summary of
high-priority items that should be addressed in the ongoing
AUC revisions. Lastly, we encourage our interventional
colleagues to identify additional methods to assess appro-
priateness and to engage in this national discussion to
enhance the applicability, credibility, and sustainability of
future AUC research. Looking forward, we believe there is
a pressing need to recreate a more comprehensive, measur-
able PCI AUC.
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